Trader consensus assigns an 89.5% implied probability that Hims & Hers will miss Q3 2026 earnings expectations ahead of the November 9 release, reflecting margin compression from the growing share of lower-margin branded GLP-1 weight-loss products and the Eucalyptus acquisition’s international revenue mix. Revenue consensus stands near $893 million, up roughly 49% year over year, yet gross margins have declined sharply from historical levels as management has guided adjusted EBITDA margins of 9–11% while noting sustained pressure on profitability. Recent quarters show a pattern of post-earnings share declines, with Q2 2026 delivering a sharp EPS miss despite a revenue beat, and analysts maintain a Hold consensus with limited upward estimate revisions. Key swing factors include whether domestic subscriber growth accelerates enough to offset dilution risks and whether the company reaffirms its full-year revenue range, which implies a lighter Q4 outcome relative to Street forecasts.